[Form 4] ENANTA PHARMACEUTICALS INC Insider Trading Activity

Rhea-AI Filing Summary

Enanta Pharmaceuticals Inc. (ENTA) reported a stock option grant to its Chief Scientific Officer on a Form 4. On November 25, 2025, the officer received a stock option to purchase 110,000 shares of Enanta common stock at an exercise price of $13.66 per share, expiring on November 25, 2035.

The option covers 110,000 underlying shares of common stock and is held directly. It becomes exercisable, subject to continued employment, in substantially equal quarterly installments over four years from the grant date, with fractional shares cumulated and becoming exercisable once a whole share equivalent is reached.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Or Yat Sun

(Last) (First) (Middle)

C/O ENANTA PHARMACEUTICALS, INC.

4 KINGSBURY AVENUE

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ENANTA PHARMACEUTICALS INC [ ENTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.66	11/25/2025		A		110,000		(1)	11/25/2035	Common Stock	110,000	$0.00	110,000	D

Explanation of Responses:

1. Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025).

	/s/ Matthew Kowalsky as attorney-in-fact	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Enanta Pharmaceuticals (ENTA) report in this Form 4 filing?

Enanta Pharmaceuticals reported that its Chief Scientific Officer received a stock option grant on November 25, 2025, as disclosed on a Form 4 filed for one reporting person.

How many Enanta (ENTA) stock options were granted and at what exercise price?

The officer received a stock option for 110,000 derivative securities, each representing one share of Enanta common stock, with an exercise price of $13.66 per share.

When do the newly granted Enanta (ENTA) stock options expire?

The stock option grant reported for the Chief Scientific Officer has an expiration date of November 25, 2035, ten years from the grant date.

What is the vesting schedule for the Enanta (ENTA) stock option grant?

The option will become exercisable, subject to the optionholder's continued employment, in substantially equal quarterly installments over four years from the November 25, 2025 grant date, with fractional shares cumulated until a whole share is available.

How many Enanta (ENTA) shares underlie the reported stock options?

The derivative security is a stock option (right to buy) that is exercisable for 110,000 shares of Enanta common stock, as stated in the table of derivative securities.

Is the Enanta (ENTA) stock option grant reported as directly owned?

Yes. The Form 4 indicates that the 110,000 stock options and the corresponding beneficial ownership are held in direct (D) form by the reporting person.